Ann: Change of Director's Interest Notice, page-38

Wasa, I don’t have the capabilities to answer your questions specifically. My opinions are always of a general nature and based on ‘gut feel’ gained from reading and attempting to interpret the researched and more objective work of those poster whom I have come to respect – much of the rest, I attempt to let pass through without influence.

FWIW, I think that if BT for Rett’s is refused the SP will drop back to the 10-12c range (rather illogically, because I do not consider BT to be the main game) and, if granted, it may settle at 20-22c range – but that is just specific guessing, which I generally do not like to do.

The main game lies in the further Phase 2 trial results. Firstly, a Rett’s like result for Fragile X would be very big, if followed by similar for TBI that would be huge, and again if followed by similar for mild concussion that would be absolutely massive – the sky would be the literal limit. Such results would erase any doubts about the efficacy of our drug within the autism spectrum and the dream of ‘aspro for the brain’ would be all but a reality. Feet back on the ground, the likelihood of this quadrella may be (very) slim, but we have the first leg in and are on a well fancied runner in the second. After that who knows?

The best part is that all the answers will most likely be provided within the next 18 months or so. At that stage our Phase 2 successes will number from a definite 1 to a possible 4 and the future outlook will be much, much clearer. As with PBT, we have got one (be it, in IMO, a far more emphatic one), but unlike PBT we have 3 more near term irons in the fire.

Just the way I see it – the science, the results to date and possible future opportunities make this one a gamble to good to pass up. The preceding is from an investment point of view, but perhaps the principal reason to cheer this company on is the untold and almost unimaginable benefits its drug will provide if it is only half as successful as we all hope.